Standard BioTools (LAB) awards 500,000 RSUs to Chief Business Officer

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Standard BioTools Inc. approved a grant of 500,000 restricted stock units to Chief Business Officer Sean Mackay under its 2026 Equity Incentive Plan, effective June 20, 2026. If he continues providing services, 40% of the award will vest on June 20, 2027 and the remaining 60% on June 20, 2028. The award is governed by the 2026 Equity Incentive Plan, its RSU agreement, and the company’s 2026 Change of Control and Severance Plan and related participation agreement.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

RSU grant size: 500,000 restricted stock units First vesting tranche: 40% of RSU award Second vesting tranche: 60% of RSU award +2 more

5 metrics

RSU grant size 500,000 restricted stock units Award to Chief Business Officer Sean Mackay effective June 20, 2026

First vesting tranche 40% of RSU award Vests on June 20, 2027, subject to continued service

Second vesting tranche 60% of RSU award Vests on June 20, 2028, subject to continued service

Plan year 2026 Equity Incentive Plan Governing plan for the RSU award

Change of control coverage 2026 Change of Control and Severance Plan Applies to Mackay and his RSU award

Key Terms

restricted stock units, 2026 Equity Incentive Plan, Change of Control and Severance Plan, Participation Agreement

4 terms

restricted stock units financial

"approved a grant of 500,000 restricted stock units for Sean Mackay"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2026 Equity Incentive Plan financial

"under the Company’s 2026 Equity Incentive Plan (the “2026 Plan”)"

Change of Control and Severance Plan financial

"subject to the provisions of the Company’s 2026 Change of Control and Severance Plan"

Participation Agreement financial

"under which Mr. Mackay participates, and his Participation Agreement thereunder"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/03/2026 - 04:05 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 29, 2026

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)


Delaware (State or other jurisdiction of incorporation or organization)	001-34180 (Commission File Number)	77-0513190 (I.R.S. Employer Identification Number)
50 Milk Street, 10th Floor Boston, Massachusetts 02109
(Address of principal executive offices and zip code)
(650) 266-6000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, $0.001 par value per share	LAB	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 29, 2026, the Human Capital Committee of the Board of Directors of Standard BioTools Inc. (the “Company”) approved a grant of 500,000 restricted stock units for Sean Mackay, Chief Business Officer of the Company, under the Company’s 2026 Equity Incentive Plan (the “2026 Plan”), effective as of June 20, 2026 (the “RSU Award”). Subject to Mr. Mackay continuing to provide services to the Company through the applicable vesting dates, 40% of the RSU Award will vest on June 20, 2027, and the remaining 60% of the RSU Award will vest on June 20, 2028.

The RSU Award is subject to the terms and conditions of the 2026 Plan and the applicable RSU Award agreement thereunder. The RSU Award is also subject to the provisions of the Company’s 2026 Change of Control and Severance Plan under which Mr. Mackay participates, and his Participation Agreement thereunder.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Date:		June 3, 2026


	STANDARD BIOTOOLS INC.

	By:		/s/ Alex Kim
	Name:		Alex Kim
	Title:		Chief Financial Officer

Source: View Original Filing on SEC EDGAR

FAQ

What executive equity award did Standard BioTools (LAB) disclose?

Standard BioTools approved a grant of 500,000 restricted stock units to Chief Business Officer Sean Mackay. The award is made under the company’s 2026 Equity Incentive Plan and is effective June 20, 2026, subject to standard service-based vesting conditions.

How do Sean Mackay’s new RSUs at Standard BioTools (LAB) vest?

The 500,000 restricted stock units vest over two years if he continues serving the company. Forty percent vests on June 20, 2027, and the remaining 60% vests on June 20, 2028, creating a staggered vesting schedule tied to ongoing employment.

Under which plans were the new LAB RSUs granted to Sean Mackay?

The RSU grant was approved under Standard BioTools’ 2026 Equity Incentive Plan. It is also subject to the company’s 2026 Change of Control and Severance Plan, in which Mackay participates, and his related Participation Agreement, alongside the specific RSU award agreement.

What role does Sean Mackay hold at Standard BioTools (LAB)?

Sean Mackay serves as Chief Business Officer of Standard BioTools Inc. The company’s Human Capital Committee approved a 500,000 restricted stock unit award for him, aligning his compensation with equity-based incentives under the 2026 Equity Incentive Plan and related arrangements.

When did Standard BioTools’ board committee approve the RSU grant for Sean Mackay?

The Human Capital Committee of Standard BioTools’ board approved the 500,000 RSU grant on May 29, 2026. The grant is effective as of June 20, 2026, with vesting dates in 2027 and 2028 contingent on continued service to the company.

Filing Exhibits & Attachments

1 document